Brain tumor clinical trials open around the country all the time, and it can be hard for patients and care partners to keep track of new opportunities to consider participation in leading-edge clinical research. This report, generated by the National Brain Tumor Society, provides a summary of clinical trials that have started or begun recruitment for patients in the U.S. with primary brain tumors since our last quarterly report. To learn more about each trial, and contact the party responsible for enrolling patients, just follow the hyperlink by clicking on the title of each trial listing.

• Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery
  • Brief Description: An early phase I clinical trial for adults 18-65 years old who are having pituitary tumor surgery at NIH to test the safety of using a new coil device to improve MRI imaging of pituitary tumors during surgery.
• HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
  • Brief Description: A phase I clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.
• Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
  • Brief Description: This phase II study investigates the feasibility of reducing radiation doses to the hippocampi (i.e., hippocampal avoidance [HA]) by using proton therapy for midline or suprasellar low-grade gliomas.
• Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
  
  • Brief Description: This phase I trial studies the side effects of nivolumab, BMS-986205, and standard radiation therapy with or without temozolomide in treating patients with new diagnosed glioblastoma.
• Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors
  
  • Brief Description: This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors, including brain cancer.
• Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
  • Brief Description: This phase II study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab.
• Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors
  • Brief Description: This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. Imaging agents, such as fluoroethyltyrosine, may help doctors see the tumor better during a positron emission tomography (PET) scan.
• Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
  • Brief Description: The purpose of this phase II study is to determine if combining the checkpoint inhibitors nivolumab and ipilimumab is an effective treatment for people with pituitary tumors that have gotten worse after surgery and radiation.
• Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
  • Brief Description: This is an NCI-funded open-label phase 2 trial using indoximod-based combination chemo-radio-immunotherapy for treatment of patients age 3 to 21 years who have progressive brain cancer (glioblastoma, medulloblastoma, or ependymoma), or newly-diagnosed diffuse intrinsic pontine glioma (DIPG).

For a more comprehensive list of ALL open brain tumor clinical trials, please visit the NBTS Clinical Trial Finder at trials.braintumor.org, where you can search potential opportunities for enrollment based on criteria important and specific to you.